BioCardia

BioCardia P/TBV

The Price to Tangible Book Value (P/TBV) of BioCardia (BCDA) as of Nov 20, 2026 is 13.52. In the previous year, Price to Tangible Book Value (P/TBV) was 14.45 — a change of -6.48% (lower).

P/TBV

13.52

YoY

-6.48%

Last updated:

Price to Tangible Book Value (P/TBV) of BioCardia is 2025 13.52 . Price to Tangible Book Value (P/TBV) of BioCardia was 2024 14.45 . It decreases by -6.48% lower compared to the previous year.

The BioCardia P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
3.19 USD
Jan 1, 2019
5.10 USD
Jan 1, 2020
0.63 USD
Jan 1, 2021
1.17 USD
Jan 1, 2022
2.47 USD
Jan 1, 2023
-7.55 USD
Jan 1, 2024
14.45 USD
Jan 1, 2025
13.52 USD
The BioCardia P/TBV history
YEARP/TBVYoY
13.52-6.48%
14.45-291.52%
-7.55-405.18%
2.47+112.08%
1.17+84.83%
0.63-87.64%
5.10+60.00%
3.19+193.38%
1.09+85.01%
0.59-32.63%
0.87-2.32%
0.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCardia stock

Price to Tangible Book Value (P/TBV) of BioCardia is 13.52 in 2025.

Price to Tangible Book Value (P/TBV) of BioCardia changed from 14.45 to 13.52, representing a -6.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) BioCardia since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s BioCardia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioCardia

All Key Metrics — BioCardia